These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11475468)

  • 1. Clinical pharmacokinetics of inhaled budesonide.
    Donnelly R; Seale JP
    Clin Pharmacokinet; 2001; 40(6):427-40. PubMed ID: 11475468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.
    Minto C; Li B; Tattam B; Brown K; Seale JP; Donnelly R
    Br J Clin Pharmacol; 2000 Aug; 50(2):116-24. PubMed ID: 10930963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler.
    Kaiser H; Aaronson D; Dockhorn R; Edsbäcker S; Korenblat P; Källén A
    Br J Clin Pharmacol; 1999 Sep; 48(3):309-16. PubMed ID: 10510140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.
    Thorsson L; Edsbäcker S; Källén A; Löfdahl CG
    Br J Clin Pharmacol; 2001 Nov; 52(5):529-38. PubMed ID: 11736861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of efficacy and safety of budesonide delivered via two dry powder inhalers.
    Kerwin EM; Pearlman DS; de Guia T; Carlsson LG; Gillen M; Uryniak T; Simonson SG
    Curr Med Res Opin; 2008 May; 24(5):1497-510. PubMed ID: 18419878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide.
    Clearie KL; Williamson PA; Meldrum K; Gillen M; Carlsson LG; Carlholm M; Ekelund J; Lipworth BJ
    Br J Clin Pharmacol; 2011 Apr; 71(4):504-13. PubMed ID: 21395643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers.
    Persson G; Ankerst J; Gillen M; Bengtsson T; Thorsson L
    Curr Med Res Opin; 2008 May; 24(5):1511-7. PubMed ID: 18419877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
    Pitcairn G; Reader S; Pavia D; Newman S
    J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma.
    Morice AH; Peterson S; Beckman O; Osmanliev D
    Int J Clin Pract; 2007 Nov; 61(11):1874-83. PubMed ID: 17887990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort
    Gillen M; Forte P; Svensson JO; Lamarca R; Burke J; Rask K; Larsdotter Nilsson U; Eckerwall G
    Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer.
    Goldberg S; Einot T; Algur N; Schwartz S; Greenberg AC; Picard E; Virgilis D; Kerem E
    Ann Allergy Asthma Immunol; 2002 Dec; 89(6):566-71. PubMed ID: 12487221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
    Tronde A; Gillen M; Borgström L; Lötvall J; Ankerst J
    J Clin Pharmacol; 2008 Nov; 48(11):1300-8. PubMed ID: 18974284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma.
    Morice AH; Hochmuth L; Ekelund J; Thorén A; Puterman AS
    Pulm Pharmacol Ther; 2008; 21(1):32-9. PubMed ID: 17118686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung deposition of budesonide from the novel dry powder inhaler Airmax.
    Hirst RH; Newman SR; Clark DA; Hertog MG
    Respir Med; 2002 Jun; 96(6):389-96. PubMed ID: 12117037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
    Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
    Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.
    Nave R; Zech K; Bethke TD
    Eur J Clin Pharmacol; 2005 May; 61(3):203-8. PubMed ID: 15824911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.